Ultrapure tetrahydrocannabinol-11-oic acids
This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.
1. A pharmaceutical composition comprising a preparation of ajulemic acid and a pharmaceutically acceptable excipient, wherein the preparation of ajulemic acid comprises at least 98% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof, wherein the preparation of ajulemic acid has a Ki for the CB1 receptor (Ki CB1) ranging from 10 times to 40 times greater than its Ki for the CB2 receptor (Ki CB2), and wherein the Ki CB1 and the Ki CB2 are each determined according to a competitive radioligand binding assay with [ 3 H]-CP55940 as the radioligand.
2. The pharmaceutical composition of claim 1 , wherein the preparation of ajulemic acid has a Ki CB1 ranging from 10 times to 20 times greater than its Ki CB2.
3. The pharmaceutical composition of claim 1 , wherein the preparation of ajulemic acid comprises at least 99% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 1 , wherein the preparation of ajulemic acid comprises less than 0.5% (w/w) of 11-hydroxy-(6aR, 10aR)-3-(1′, 1-dimethylheptyl)-Δ8-tetrahydrocannabinol (HU-210).
5. The pharmaceutical composition of claim 4 , wherein the preparation of ajulemic acid comprises less than 0.1% (w/w) of 11-hydroxy-(6aR, 10aR)-3-(1′, 1-dimethylheptyl)-Δ8-tetrahydrocannabinol (HU-210).
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a tablet or a capsule.
7. The pharmaceutical composition of claim 6 , wherein the tablet or the capsule comprises from 5 mg to 180 mg of the preparation of ajulemic acid or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a preparation of ajulemic acid and a pharmaceutically acceptable excipient, wherein the preparation of ajulemic acid comprises at least 98% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof, wherein the preparation of ajulemic acid has a Ki for the CB1 receptor (Ki CB1) of 628 nM or more and a Ki for the CB2 receptor (Ki CB2) of 100 nM or less, and wherein the Ki CB1 and the Ki CB2 are each determined according to a competitive radioligand binding assay with [ 3 H]-CP55940 as the radioligand.
9. The pharmaceutical composition of claim 8 , wherein the preparation of ajulemic acid has a Ki CB2 of 60 nM or less.
10. The pharmaceutical composition of claim 9 , wherein the preparation of ajulemic acid has a Ki CB2 of 51 nM or less.
11. A method of treating a subject having a fibrotic disease or an inflammatory disease, the method comprising administering to the subject the pharmaceutical composition of claim 1 .
12. A method of treating a subject having a fibrotic disease or an inflammatory disease, the method comprising administering to the subject the pharmaceutical composition of claim 8 .
13. A method of treating a subject having a fibrotic disease or an inflammatory disease, the method comprising administering to the subject the pharmaceutical composition of claim 10 .
14. A pharmaceutical composition comprising a preparation of ajulemic acid and a pharmaceutically acceptable excipient, wherein the preparation of ajulemic acid comprises at least 98% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof, wherein the preparation of ajulemic acid has a Ki for the CB1 receptor (Ki CB1) ranging from 5 times to 50 times greater than its Ki for the CB2 receptor (Ki CB2), and wherein the Ki CB1 and the Ki CB2 are each determined according to a competitive radioligand binding assay with [ 3 H]-CP55940 as the radioligand.
15. The pharmaceutical composition of claim 14 , wherein the preparation of ajulemic acid comprises at least 99% (w/w) ajulemic acid or a pharmaceutically acceptable salt thereof.
16. The pharmaceutical composition of claim 14 , wherein the preparation of ajulemic acid comprises less than 0.5% (w/w) of 11-hydroxy-(6aR, 10aR)-3-(1′, 1-dimethylheptyl)-Δ8-tetrahydrocannabinol (HU-210).
17. The pharmaceutical composition of claim 16 , wherein the preparation of ajulemic acid comprises less than 0.1% (w/w) of 11-hydroxy-(6aR, 10aR)-3-(1′, 1-dimethylheptyl)-Δ8-tetrahydrocannabinol (HU-210).
18. A method of treating a subject having a fibrotic disease or an inflammatory disease, the method comprising administering to the subject the pharmaceutical composition of claim 14 .